期刊文献+

熊果酸液固压缩片的制备及优势 被引量:4

Preparation and Advantages of Ursolic Acid Liquid- Solid Compressed Tablets
下载PDF
导出
摘要 目的优选制备熊果酸液固压缩片的处方并探讨其优势。方法用不同处方制备熊果酸液固压缩片,同时与普通片剂进行片剂质量和溶出度比较。结果液固压缩片较普通片剂的溶出度大幅度提高,在45 min时最多可提高214%;片剂质量在崩解时限、重量差异等方面均明显优于普通片剂,崩解时限至少缩短一半。结论液固压缩技术可应用于难溶性药物熊果酸的制剂,且具有一定优势。 Objective To prepare the prescription of Ursolic Acid Liquid- Solid Compressed Tablets and to explore its advantages. Methods The preparation of Ursolic Acid Liquid- Solid Compressed Tablets was investigated by different prescriptions. At the same time, its quality and dissolution rate were compared with those of the ordinary tablets. Results The dissolution rate of the liquid- solid compressed tablets was increased by a large margin than the ordinary tablets, which was increased by 214% in 45 min, at most by 214%. The compressed tablets quality is significantly superior to the ordinary tablets in the aspects of the disintegration time limit and the weight difference, etc. The disintegration time limit was cut in half th time. Conclusion The liquid- solid compression technique can be applied to the preparations of poorly soluble drug ursolic acid and has certain advantages.
出处 《中国药业》 CAS 2014年第1期33-35,共3页 China Pharmaceuticals
关键词 熊果酸 聚乙二醇400 1 2-丙二醇 片剂质量 溶出度 ursol ic acid PEG400 1, 2 - propylene glycol tablet quality dissolution rate
  • 相关文献

参考文献11

  • 1Syed IA,Pavani E. The liquisolid technique:based drug delivery system[J].J Inter Pharm Sci and Drug Res,2012,(2):88-96.
  • 2Spireas S. Liquisolid systems and methods of preparing same[P].US:US6423339B1,2002.
  • 3Spireas S,Sadu S. Enhancement of prednisolone dissolution properties using liquisolid compacts[J].{H}Journal of Pharmaceutical Sciences,1998,(2):177-188.
  • 4王建新.化妆品天然功能成分[M]{H}北京:化学工业出版社,2007268-269.
  • 5纵伟,赵光远,张文叶.功能性食品因子熊果酸研究进展[J].食品工程,2006(2):14-16. 被引量:15
  • 6Vajir S,Sahu V,Ghuge N. Liquisolid compact:a new technique for enhancement of drug dissolution[J].Iran J Pharm Res Drug,2011,(3):302-306.
  • 7Saeedi M,Akbari J,Morteza-Semnani K. Enhancement of Dissolution Rate of Indomethacin Using Liquisolid Compacts[J].Iran J Pharm Res,2011,(1):25-34.
  • 8Yadav VB,Yadav AV. Liquisolid granulation technique for tablet manufacturing:an overview[J].Iran J Pharm Res,2009,(4):670-674.
  • 9Akinlade B,Elkordy AA,Essa EA. Liquisolid Systems to Improve the Dissolution of Furosemide[J].Sci Pharm,2010.325-344.
  • 10国家药典委员会.中华人民共和国药典(二部)[M]{H}北京:中国医药科技出版社,2010附录X83-附附录89.

二级参考文献19

  • 1任秀莲,魏琦峰,周春山,钟世安,董朝青.沉淀吸附法提取苦丁茶中的熊果酸[J].中南大学学报(自然科学版),2004,35(4):599-603. 被引量:23
  • 2熊筱娟,陈武,郑国安,张俊明,易增兴,郭晟.乌索酸的一般药理学实验研究[J].江西师范大学学报(自然科学版),2005,29(1):81-84. 被引量:15
  • 3林海禄,罗明标,刘淑娟,刘云海.HPLC法快速测定车前草中熊果酸的含量[J].食品工业科技,2005,26(5):171-172. 被引量:8
  • 4Naomi Y,Yuhji T,Harumi K,et al.Dissolution behavior of probucol from solid dispersion systems probucolpolyvinylpyrrolidone[J].Chem Pharm Bull,1996,44(1):241-244 .
  • 5于华中 李国章 曹庸 等.薄层扫描法测定几种植物中熊果酸的含量[J].中国林副特产,2000,76(3):25-25.
  • 6AQUINQ R, DE TOMMASE N, DE SIMINE F.Triterpenes and quinovic acid glycosides from Uncaria tomentosa [J]. Phytochemistry, 1997,45(5):1 035- 1 040.
  • 7MARTIN-ARAGON S,DE LAS HERAS B,SANCHEZ-REUS MI,et al. Pharmacological modification of endogenous antioxidant enzymes ursolic acid on tetrachloride- induced liver damage in rats and primary cultures of rat hepatocytes [J]. Exp Toxicol Pathol,2001,53 (2-3): 199-206.
  • 8GAO J,TANG X,DOU H,et al.Hepatoprotective activity of Terminalia catappa L.eaves and its two triterpenoids [J]. J Pharm Pharmacol, 2004, 56(11):1 449 - 1 455.
  • 9CHATOPADHYAY D,ARUNACHALAM G, MANDAL AB, et al.Antimicrobial and anti-inflammatory activity of folklore: Malotus peltatus leaf extract [J].J Ethnopharmacol, 2002,82 (2-3): 229 - 237.
  • 10KASHIWADA Y, NAGAO T, HASHIMOTO A, et al.Anti-AIDS agents 38. Anti-HIV activity of 3-o-acyl ursolic acid derivatives [J].J Nat Pro, 2000, 63 (12):1 619-1 622.

共引文献26

同被引文献14

  • 1Spireas S, Sadu S, Grover R. In vitro release evaluation of hydrocortisone liquisolid tablets [ J ]. J Pharm Sci-US, 1998,87 ( 7 ) : 867-872.
  • 2Spireas S, Sadu S. Enhancement of prednisolone dissolution properties using liquisolid compacts [J].Iran J Pharm Res,1995,166(2) :177-188.
  • 3Khalid M, Samy A M, Fetouh M I. Formulation and evaluation of Rofecoxib liquisolid tablets [ J ]. Iran J Pharm Res ,2010,3 ( 1 ) : 135-142.
  • 4Saeedi M, Akbari J, Morteza-Semnani K, et al. Enhancement of dissolution rate of indomethacin: using liquisolid compacts [J].Iran J Pharm Res, 2011, 10 ( 1 ) :25-34.
  • 5Kulkarni A S, Gaja J B. Formulation and evaluation of liquisolid compacts of dielofenac sodium [J].PDA J Pharm Sci Tech, 2010,64 ( 3 ) : 222-232.
  • 6Patel V P, Patel N M. Dissolution enhancement of glipizide using Liquisolid tablet technology [J]. Indian Drugs, 2008,45 ( 4 ) : 318-323.
  • 7Tiong N, Elkordy A A. Effects of liquisolid formulations on dissolution of naproxen [ J ]. Eur J Pharm Biopharm, 2009,73 ( 3 ) : 373 -384.
  • 8Gubbi S R, Jarag R. Formulation and characterization of atorvastatin calcium liquisolid compacts [ J ]. Asian J Pharm Sei, 2010,5 ( 2 ) :50-60.
  • 9李丽然,王成港,郭红,任晓文.液固压缩技术在药剂学中的应用[J].现代药物与临床,2012,27(3):283-286. 被引量:11
  • 10赵许杰,闫雪生,徐新刚,崔兵兵.液固压缩技术速释α-细辛脑的机制探讨[J].中国实验方剂学杂志,2013,19(14):56-58. 被引量:6

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部